Valcourt Behavioral Health - Medicare Mental Health Clinic in Miami Lakes, FL

Valcourt Behavioral Health is a medicare enrolled mental health clinic (Community/behavioral Health) in Miami Lakes, Florida. The current practice location for Valcourt Behavioral Health is 6600 Cow Pen Rd Ste 250, Miami Lakes, Florida. For appointments, you can reach them via phone at (305) 764-0194. The mailing address for Valcourt Behavioral Health is 6600 Cow Pen Rd Ste 250, Miami Lakes, Florida and phone number is (305) 764-0194.

Valcourt Behavioral Health is licensed to practice in * (Not Available) (license number ). The clinic also participates in the medicare program and its NPI number is 1548591928. This medical practice accepts medicare insurance (which means this clinic accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance). However, please confirm if they accept your insurance at (305) 764-0194.

Contact Information

Valcourt Behavioral Health
6600 Cow Pen Rd Ste 250
Miami Lakes
FL 33014-7622
(305) 764-0194
Not Available

Mental Health Clinic Profile

Full NameValcourt Behavioral Health
SpecialityCommunity/Behavioral Health
Location6600 Cow Pen Rd Ste 250, Miami Lakes, Florida
Authorized Official Name and PositionJorge E Valcourt (OWNER)
Authorized Official Contact3057640194
Accepts Medicare InsuranceYes. This clinic participates in medicare program and accept medicare insurance.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Valcourt Behavioral Health
6600 Cow Pen Rd Ste 250
Miami Lakes
FL 33014-7622

Ph: (305) 764-0194
Valcourt Behavioral Health
6600 Cow Pen Rd Ste 250
Miami Lakes
FL 33014-7622

Ph: (305) 764-0194

NPI Details:

NPI Number1548591928
Provider Enumeration Date01/25/2010
Last Update Date06/12/2023
Certification Date06/12/2023

Medicare PECOS Information:

Medicare PECOS PAC ID4284778978
Medicare Enrollment IDO20100218000541

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

Medical Identifiers

Medical identifiers for Valcourt Behavioral Health such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1548591928NPI-NPPES
104359100MedicaidFL

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
103TA0700XPsychologist - Adult Development & Aging (* (Not Available))Secondary
103TF0000XPsychologist - Family (* (Not Available))Secondary
103TP2701XPsychologist - Group Psychotherapy (* (Not Available))Secondary
106H00000XMarriage & Family Therapist (* (Not Available))Secondary
2084P0804XPsychiatry & Neurology - Child & Adolescent Psychiatry (* (Not Available))Secondary
251S00000XCommunity/behavioral Health (* (Not Available))Primary
261QM0801XClinic/center - Mental Health (including Community Mental Health Center) (* (Not Available))Secondary
322D00000XResidential Treatment Facility, Emotionally Disturbed Children PY7537 (Florida)Secondary

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Valcourt Behavioral Health acts as a billing entity for following providers:
Provider NameJose C Lopez
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1669515730
PECOS PAC ID: 8325959117
Enrollment ID: I20031113000680

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

Provider NameGuido Nodal
Provider TypePractitioner - Psychiatry
Provider IdentifiersNPI Number: 1427064435
PECOS PAC ID: 7911999404
Enrollment ID: I20040402000684

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

Provider NameMaria L Valcourt-rodriguez
Provider TypePractitioner - Clinical Psychologist
Provider IdentifiersNPI Number: 1124216858
PECOS PAC ID: 6103908736
Enrollment ID: I20080204000634

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

Provider NameIvon Leon
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1043724685
PECOS PAC ID: 4587925748
Enrollment ID: I20180302002149

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

Provider NameLori Diana Mestre
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1235423294
PECOS PAC ID: 2769733427
Enrollment ID: I20180920000026

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

Provider NameDiana M Saavedra
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1386119402
PECOS PAC ID: 7214279066
Enrollment ID: I20190429000560

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

Provider NameAdara C Abdalah
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1295321412
PECOS PAC ID: 0749675262
Enrollment ID: I20220321001261

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

Provider NameDaniel Santos Frutos
Provider TypePractitioner - Nurse Practitioner
Provider IdentifiersNPI Number: 1952064115
PECOS PAC ID: 4789061904
Enrollment ID: I20220509002596

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

Provider NameMiguel Danois
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1982315776
PECOS PAC ID: 0547631061
Enrollment ID: I20230120000694

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more Medical News

› Verified 3 days ago

News Archive

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

Four PhD graduates to showcase cutting-edge research in University of Leicester lectures

The University of Leicester has announced its upcoming Doctoral Inaugural Lectures for 2011, which celebrate and showcase four doctoral graduates who are both outstanding academically and able to present their work in a way that is accessible and engaging. The speakers will talk about their doctoral research, with subjects including: personalising asthma prescriptions, understanding growth disorders of bodily organs, building models of human brain function and defining the mechanisms of pollen fertility in plants.

Read more News

› Verified 3 days ago

Community/Behavioral Health in Miami Lakes, FL

Permuy Diversity Interventions Llc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 8760 Nw 146th Ln, Miami Lakes, FL 33018
Phone: 786-238-5931    
Productive Minds Llc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 6625 Miami Lakes Dr, Miami Lakes, FL 33014
Phone: 305-998-9806    
Jcv Behavior Services Llc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 6625 Miami Lakes Dr Ste 226, Miami Lakes, FL 33014
Phone: 305-777-3884    Fax: 305-777-3885
Limitless Growth Llc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 14100 Palmetto Frntg Rd Ste 112, Miami Lakes, FL 33016
Phone: 786-837-3540    
Children Behavioral Therapy Services Llc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 7779 Nw 146th St, Miami Lakes, FL 33016
Phone: 786-702-6868    
Bosc Mental Health, Llc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 15233 Nw 87th Ct, Miami Lakes, FL 33018
Phone: 786-643-3835    Fax: 305-470-7457
Second Chance Case Management Inc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 15485 Eagle Nest Ln Ste 150, Miami Lakes, FL 33014
Phone: 178-302-5424    Fax: 786-396-5317

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.